/
CCCC
$4.35+$0.09 (+2.11%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$471.0M
111M shares
52-week range
$1.40 – $4.60
92% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.55%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-34.46
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $19.4M | $21.4M | $33.2M | $45.8M | $31.1M | $20.8M | $35.6M | $35.9M |
| Cost of revenue | $28.6M | $0 | $78.4M | $0 | $0 | $7.7M | $0 | $8.0M |
| Gross profit | −$9.2M | $21.4M | −$45.2M | $45.8M | $31.1M | $13.0M | $35.6M | $28.0M |
| Gross margin | -47.7% | 100.0% | -136.3% | 100.0% | 100.0% | 62.7% | 100.0% | 77.8% |
| R&D | $28.6M | $48.1M | $78.4M | $94.7M | $117.8M | $117.7M | $110.6M | $104.2M |
| Operating income | −$16.4M | −$35.5M | −$60.4M | −$82.1M | −$129.5M | −$139.0M | −$119.6M | −$104.5M |
| EBITDA | −$15.1M | −$31.7M | −$58.8M | −$80.3M | −$124.3M | −$122.1M | −$103.4M | −$102.9M |
| Net income | −$15.7M | −$34.1M | −$66.3M | −$83.9M | −$128.2M | −$132.5M | −$105.3M | −$105.0M |
| Net margin | -81.1% | -159.5% | -199.8% | -183.2% | -412.2% | -638.3% | -296.0% | -292.1% |
| EPS (diluted) | -1.06 | -0.79 | -1.54 | -1.82 | -2.62 | -2.67 | -1.52 | -1.27 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $23M | $-0.93 | $-0.97–$-0.89 | 4 |
| 2027 | $19M | $-1.01 | $-1.08–$-0.92 | 4 |
| 2028 | $17M | $-1.22 | $-1.71–$-0.85 | 5 |
| 2029 | $628M | $0.39 | $0.26–$0.51 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
C4 Therapeutics, Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
www.c4therapeutics.com- Employees
- 104
- IPO / List date
- Oct 2, 2020
- HQ
- WATERTOWN, MA
Held by traders on TradeandTell
No one on the platform currently holds CCCC.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 2,461,815 | $6.5M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded CCCC yet.
